Veterinary Pain Management Drugs Market - 2024-2031
Veterinary Pain Management Drugs Market reached US$ 2.06 billion in 2023 and is expected to reach US$ 3.00 billion by 2031, growing with a CAGR of 4.80% during the forecast period 2026-2031.
The Veterinary Pain Management Drugs Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Veterinary Pain Management Drugs Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Drug Type
Both primary and secondary data sources have been used in the global Veterinary Pain Management Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Veterinary Pain Management Drugs Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Veterinary Pain Management Drugs Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Drug Type
- NSAIDS*
- Meloxicam
- Deracoxib
- Carprofen
- Etodolac
- Firocoxib
- Others
- Opioids
- Morphine
- Codeine
- Fentanyl
- Buprenorphine
- Local Anesthetics
- Lidocaine
- Bupivacaine
- Mepivacaine
- Alpha-2 Agonists
- Medetomidine
- Xylazine
- Romifidine
- Disease Modified Osteoarthritis Drugs (DMOAD)
- Oral*
- Parenteral
- Topical
- Companion Animal*
- Dogs
- Cats
- Horses
- Other Companion Animals
- Livestock
- Cattle
- Swine
- Other Livestock Animals
- Postoperative Pain*
- Joint Pain
- Osteoarthritis
- Musculoskeletal Disorders
- Cancer
- Other
- Veterinary Hospitals & Clinics*
- Retail Pharmacies
- Online Pharmacies
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Veterinary Pain Management Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet by Drugs
3.2. Market Snippet by Route of Administration
3.3. Market Snippet by Animal
3.4. Market Snippet by Application
3.5. Market Snippet by Distribution Channel
3.6. Market Snippet by Region
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.2. Drivers
4.2.1. Rising Prevalence of Painful and Inflammatory Diseases in Animals
4.2.2. Increasing Initiatives towards Animal Healthcare
4.2.3. Increasing number of companion animal ownership
4.3. Restraints
4.3.1. Side Effects Associated with Drugs
4.3.2. Changes in Distribution Channel
4.4. Opportunity
4.5. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
5.4. Pricing Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY DRUG TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
7.1.2. Market Attractiveness Index, By Drug Type Segment
7.2. NSAIDS*
7.2.1. Introduction
7.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
7.2.3. Meloxicam
7.2.4. Deracoxib
7.2.5. Carprofen
7.2.6. Etodolac
7.2.7. Firocoxib
7.2.8. Others
7.3. Opioids
7.3.1. Morphine
7.3.2. Codeine
7.3.3. Fentanyl
7.3.4. Buprenorphine
7.3.5. Others
7.4. Local Anesthetics
7.4.1. Lidocaine
7.4.2. Bupivacaine
7.4.3. Mepivacaine
7.4.4. Others
7.5. Alpha-2 Agonists
7.5.1. Medetomidine
7.5.2. Xylazine
7.5.3. Romifidine
7.5.4. Others
7.6. Disease Modified Osteoarthritis Drugs (DMOAD)
7.6.1. Others
8. BY ROUTE OF ADMINISTRATION
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
8.1.2. Market Attractiveness Index, By Route of Administration Segment
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
8.3. Parenteral
8.4. Topical
9. BY ANIMAL
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Segment
9.1.2. Market Attractiveness Index, By Animal Segment
9.2. Companion Animal*
9.2.1. Introduction
9.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
9.2.3. Dogs
9.2.4. Cats
9.2.5. Horses
9.2.6. Other Companion Animals
9.3. Livestock
9.3.1. Cattle
9.3.2. Swine
9.3.3. Other Livestock Animals
10. BY APPLICATION
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
10.1.2. Market Attractiveness Index, By Application Segment
10.2. Postoperative Pain*
10.2.1. Introduction
10.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
10.3. Joint Pain
10.3.1. Osteoarthritis
10.3.2. Musculoskeletal Disorders
10.4. Cancer
10.5. Other
11. BY DISTRIBUTION CHANNEL
11.1. Introduction
11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
11.1.2. Market Attractiveness Index, By Distribution Channel Segment
11.2. Veterinary Hospitals & Clinics*
11.2.1. Introduction
11.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies
12. BY REGION
12.1. Introduction
12.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
12.2.8.1. U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
12.3.8.1. Germany
12.3.8.2. U.K.
12.3.8.3. France
12.3.8.4. Italy
12.3.8.5. Spain
12.3.8.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia Pacific
12.6. The Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
13. COMPETITIVE LANDSCAPE
13.1. Competitive Scenario
13.2. Key Strategies adopted by Manufacturers
13.3. Market Positioning/Share Analysis
13.4. Product Benchmarking
14. COMPANY PROFILES
14.1. Dechra Pharmaceuticals*
14.1.1. Company overview
14.1.2. Procedure portfolio and description
14.1.3. Key highlights
14.1.4. Financial overview
14.2. Zoetis
14.3. Elanco
14.4. Boehringer Ingelheim
14.5. Vetoquinol S.A.
14.6. Ceva Sante Animale S.A.
14.7. Bayer AG
14.8. Merck Animal Health
14.9. Norbrook Laboratories
14.10. Chanelle Pharma
14.11. Virbac
14.12. Assisi Animal Health
15. DATAM INTELLIGENCE
15.1. Appendix
15.2. About Us and Services
15.3. Contact Us
1.1. Research methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet by Drugs
3.2. Market Snippet by Route of Administration
3.3. Market Snippet by Animal
3.4. Market Snippet by Application
3.5. Market Snippet by Distribution Channel
3.6. Market Snippet by Region
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.2. Drivers
4.2.1. Rising Prevalence of Painful and Inflammatory Diseases in Animals
4.2.2. Increasing Initiatives towards Animal Healthcare
4.2.3. Increasing number of companion animal ownership
4.3. Restraints
4.3.1. Side Effects Associated with Drugs
4.3.2. Changes in Distribution Channel
4.4. Opportunity
4.5. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
5.4. Pricing Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY DRUG TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
7.1.2. Market Attractiveness Index, By Drug Type Segment
7.2. NSAIDS*
7.2.1. Introduction
7.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
7.2.3. Meloxicam
7.2.4. Deracoxib
7.2.5. Carprofen
7.2.6. Etodolac
7.2.7. Firocoxib
7.2.8. Others
7.3. Opioids
7.3.1. Morphine
7.3.2. Codeine
7.3.3. Fentanyl
7.3.4. Buprenorphine
7.3.5. Others
7.4. Local Anesthetics
7.4.1. Lidocaine
7.4.2. Bupivacaine
7.4.3. Mepivacaine
7.4.4. Others
7.5. Alpha-2 Agonists
7.5.1. Medetomidine
7.5.2. Xylazine
7.5.3. Romifidine
7.5.4. Others
7.6. Disease Modified Osteoarthritis Drugs (DMOAD)
7.6.1. Others
8. BY ROUTE OF ADMINISTRATION
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
8.1.2. Market Attractiveness Index, By Route of Administration Segment
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
8.3. Parenteral
8.4. Topical
9. BY ANIMAL
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Segment
9.1.2. Market Attractiveness Index, By Animal Segment
9.2. Companion Animal*
9.2.1. Introduction
9.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
9.2.3. Dogs
9.2.4. Cats
9.2.5. Horses
9.2.6. Other Companion Animals
9.3. Livestock
9.3.1. Cattle
9.3.2. Swine
9.3.3. Other Livestock Animals
10. BY APPLICATION
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
10.1.2. Market Attractiveness Index, By Application Segment
10.2. Postoperative Pain*
10.2.1. Introduction
10.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
10.3. Joint Pain
10.3.1. Osteoarthritis
10.3.2. Musculoskeletal Disorders
10.4. Cancer
10.5. Other
11. BY DISTRIBUTION CHANNEL
11.1. Introduction
11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
11.1.2. Market Attractiveness Index, By Distribution Channel Segment
11.2. Veterinary Hospitals & Clinics*
11.2.1. Introduction
11.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies
12. BY REGION
12.1. Introduction
12.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
12.2.8.1. U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
12.3.8.1. Germany
12.3.8.2. U.K.
12.3.8.3. France
12.3.8.4. Italy
12.3.8.5. Spain
12.3.8.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia Pacific
12.6. The Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
13. COMPETITIVE LANDSCAPE
13.1. Competitive Scenario
13.2. Key Strategies adopted by Manufacturers
13.3. Market Positioning/Share Analysis
13.4. Product Benchmarking
14. COMPANY PROFILES
14.1. Dechra Pharmaceuticals*
14.1.1. Company overview
14.1.2. Procedure portfolio and description
14.1.3. Key highlights
14.1.4. Financial overview
14.2. Zoetis
14.3. Elanco
14.4. Boehringer Ingelheim
14.5. Vetoquinol S.A.
14.6. Ceva Sante Animale S.A.
14.7. Bayer AG
14.8. Merck Animal Health
14.9. Norbrook Laboratories
14.10. Chanelle Pharma
14.11. Virbac
14.12. Assisi Animal Health
15. DATAM INTELLIGENCE
15.1. Appendix
15.2. About Us and Services
15.3. Contact Us
